2020
Immuron (ASX:IMC) enters research agreement with Monash University
15 December 2020
Immuron (IMC) has entered a research agreement with Monash University to evaluate the efficacy of IMM-124E and advance SARS-CoV-2 findings.
Could Immuron’s (ASX:IMC) traveller’s diarrhoea treatment be used to fight COVID-19?
21 July 2020
Immuron’s (IMC) share price has more than doubled on the news a drug used in its traveller’s diarrhoea formulation neutralises activity aginst the COVID-19 virus.
Immuron reveals anti-COVID potential, raises $28 million
20 July 2020
Hot on the heels of reporting anti-Covid-19 action by one of the drugs it is developing, biotechnology company Immuron has raised $28 million (US$20 million) from institutional investors.
Diarrhea: A major health issue for Americans travelling abroad
12 February 2020
Research surveys have shown that around one in four travellers changes their travel itinerary due to diarrhoea and around 5% have to seek medical attention.
Walter Reid Army Institute of Research 2019 Year in Review
15 January 2020
The WRAIR provides unique research capabilities and innovative medical solutions to a range of Force Health Protection and Readiness challenges currently facing U.S. Service Members, along with threats anticipated during future operations.
Immuron partnering with Walter Reid Army Institute of Research to test Travelan against Shigella, ETEC, Vibrio cholerae and Campylobacter jejuni isolates (2020, WRAIR's Investigator's Dispatch)
1 January 2020
The WRAIR provides unique research capabilities and innovative medical solutions to a range of Force Health Protection and Readiness challenges currently facing U.S. Service Members, along with threats anticipated during future operations.
